Elizabeth Martínez-Jurado

Instituto Nacional de Neurología y Neurocirugía

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Dulce Anabel Espinoza-López

Instituto Nacional de Neurología y Neurocirugía

R. Huerta-Franco

Universidad de Guanajuato

Juan Manuel Márquez-Romero

Mexican Social Security Institute

Elizabeth Soto Cabrera

Mexican Social Security Institute

Juan Manuel Calleja

Instituto Nacional de Neurología y Neurocirugía

F. Zermeño–Pöhls

Instituto Nacional de Neurología y Neurocirugía

Fernando Zermeño

Instituto Nacional de Neurología y Neurocirugía

Mayela Rodríguez‐Violante

Instituto Nacional de Neurología y Neurocirugía

Héctor Orrego

Instituto Nacional de Neurología y Neurocirugía

Nayelli Arguelles-Morales

Instituto Nacional de Neurología y Neurocirugía

Cooperative Institutions

Instituto Nacional de Neurología y Neurocirugía

Asociación Mexicana de Psicología y Desarrollo Comunitario

Mexican Social Security Institute

German Center for Neurodegenerative Diseases

Centre for Movement Disorders

Anderson Orthopaedic Clinic

Institute for Neurodegenerative Disorders

University of Toronto

Toronto Western Hospital

University of Chile

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A Clinical Prognostic Scoring System for Neurocysticercosis (P04.236)

Neurology (2013)

Juan Manuel Márquez-Romero R. Huerta-Franco Elizabeth Soto Cabrera Fernando Zermeño Elizabeth Martínez-Jurado

OBJECTIVE: Our purpose was to construct a simple and reliable prognostic scale for neurocysticercosis.

Neurocysticercosis

Taenia solium

Univariate

Univariate analysis

Albendazole

10.1212/wnl.80.7_supplement.p04.236

Cite

Citations (0)

A Clinical Prognostic Scoring System for Neurocysticercosis

Journal of Neurosciences in Rural Practice (2021)

Juan Manuel Márquez-Romero R. Huerta-Franco Elizabeth Soto-Cabrera Dulce Anabel Espinoza-López Héctor Orrego

Abstract Objectives In patients with neurocysticercosis (NCC), an accurate risk prediction would allow a better therapeutic approach; however, there are currently no tools that can enhance the accuracy of risk prediction. We designed a prognostic scoring system to be used by neurologists and other physicians managing patients with NCC. Materials and Methods Using data from clinical records of patients from a third-level national reference center for neurological diseases, we assessed demographic, clinical, and tomographic variables among 293 patients diagnosed with NCC. Multivariable logistic regression analyses were used to develop a clinical prognostic scoring instrument. Patients with NCC were assessed for neurological impairment at 3 months after diagnosis. Statistical Analysis Score accuracy was assessed by receiver operating characteristic (ROC) curve analysis. The primary outcome was the presence of neurological impairment, resulting in disability according to self-report or caregiver reports; this outcome was assessed during follow-up visits at 3 ± 1 months after discharge. Results The most common symptoms at presentation were headache (67%) and seizure (63%). A six-item (total score from –4 to + 2) prognostic instrument was constructed on the basis of the presence of seizures/headache at presentation, a leukocyte count above 12x 109/dL, the presence of six to ten parasites, subarachnoid localization, and the use of anthelmintic drugs. Among 113 patients with negative scores, 79.6% developed neurological deficits. Among patients with scores of 1 to 2, 64.6% recovered completely, with an overall accuracy of prediction of 74.7% and area under the ROC curve = 0.722 (95% CI, 0.664–0.780, p < 0.0001). Conclusions The clinical prognostic scoring system for NCC described in this study is a new instrument for use in daily clinical practice. It is simple to administer, and it has a prognostic accuracy of 75%. Its use has the potential to improve the quality of care by guiding appropriate decision-making and early management of patients with NCC.

Neurocysticercosis

10.1055/s-0040-1718845

Cite

Citations (0)

Calidad de vida en pacientes con enfermedad de Parkinson

DELETED (2010)

Elizabeth Martínez-Jurado Amin Cervantes‐Arriaga Mayela Rodríguez‐Violante

Quality of life in patients with Parkinson's Quality of life in patients with Parkinson's Quality of life in patients with Parkinson's Quality of life in patients with Parkinson's Quality of life in patients with Parkinson's disease ABSTRACT Parkinson's disease (PD) is a disabling and progressive neurological disorder with diverse motor and nonmotor symptoms that affect patient's functionality as well as their expectatives about their phscial, mental and social well being which in turn impactsdirectly on the quality of life. There is currently no cure for PD and therefore the objective of management is aimed at reducing symptoms and neutralizing their effects on quality of life. Clinical instruments have been developed in order to measure quality of life in patients with PD that allow us to comprehensively assess not only the clinical but also the effect of treatment and other interventions in their daily life activities. This paper describes the properties and characteristics of existing clinimetric instruments for assessing the quality of life of patients with PD, as well as the main factors determining it.

Motor symptoms

Source

Cite

Citations (13)

Time to recanalisation in patients with cerebral venous thrombosis under anticoagulation therapy

Journal of Neurology Neurosurgery & Psychiatry (2015)

Antonio Araúz Juan Camilo Vargas‐González Nayelli Arguelles-Morales Miguel A. Barboza Juan Manuel Calleja

Few studies have investigated the rates of recanalisation after cerebral venous thrombosis (CVT). Our objective was to investigate the recanalisation rate and to identify predictors of recanalisation in patients with CVT.We included 102 patients with confirmed first-ever, non-septic CVT. All patients received anticoagulation for 12 months or until complete recanalisation. To assess recanalisation, patients underwent MR venography every 3 months until partial or complete recanalisation or for 12 months after diagnosis. We conducted two parallel analyses of complete recanalisation versus partial and no recanalisation versus any recanalisation. As a secondary objective we explored the influence of recanalisation on outcome and recurrent events. We calculated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysis using a Cox model.The mean age of patients was 33.5±11 years (80 (78.4%) women). Survival analysis indicated that 50% of the patients had any recanalisation (grades I, II and III) by 64 days and complete recanalisation (grade III) by 169 days. Adjusted Cox proportional model revealed that age <50 years (HR=11.5 95% CI=1.58 to 84.46, p=0.01) and isolated superior sagittal sinus thrombosis (HR=0.39, 95% CI=0.14 to 1.04, p=0.05) predict complete recanalisation, while age <50 years (HR=4.79; 95% CI=1.69 to 13.5, p=0.003) predicts any recanalisation. Patients with complete recanalisation had a greater chance of good functional outcome (HR=5.17; 95% CI=2.8 to 9.53, p<0.001).We found that recanalisation occurs over time, until month 11. Complete recanalisation may influence functional outcome.

10.1136/jnnp-2014-310068

Cite

Citations (66)